Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Sep 26

2021

Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

Hua Medicine (the "Company", or "Hua Medicine", SEHK stock code: 2552.HK) today announced that at the 6th China BioMed Innovation and Investment Conference (the "CBIIC"), Professor Jianhua MA, Director of the Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers, presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission.

Sep 23

2021

Hua Medicine's SEED Researchers to Present Key Research Results on Diabetes Remission at the China BioMed Innovation and Investment Conference

Hua Medicine (the "Company", SEHK stock code: 2552.HK) today announced that at the 6th China BioMed Innovation and Investment Conference to be held on September 25-27, 2021 in Suzhou, China (the "CBIIC"), select researchers participating in the Hua Medicine Phase III SEED Study ("SEED Study", also known as HMM0301)

Sep 15

2021

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). Under the agreement both companies will cooperate more closely in logistics warehousing, supply chain management and channel data analysis, and will jointly promote the commercialization of Hua Medicine's global first-in-class glucokinase activator (GKA), dorzagliatin, for its market launch in China.

Aug 19

2021

Hua Medicine Announces 2021 Interim Results

Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period").

Jun 21

2021

Hua Medicine to present additional dorzagliatin trials data at ADA 2021

Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the Company will be giving 3 important presentations, presenting additional clinical data from several trials of its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 81st American Diabetes Association (ADA) Annual Scientific Sessions.

May 31

2021

Hua Medicine to present additional dorzagliatin data at ADA 2021

Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the Company will present additional clinical research analysis data of its world's first new drug, glucokinase activator (GKA) dorzagliatin, at the 81st American Diabetes Association (ADA) Annual Scientific Sessions. The ADA Annual Scientific Sessions will be held online from June 25 to 29, 2021.

Apr 23

2021

Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally

Hua Medicine (the "Company，"Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). Dorzagliatin is the first glucokinase activator (GKA) to submit a NDA for the treatment of diabetes, and has the potential to become the first first-in-class drug to be launched in China.

Mar 19

2021

Hua Medicine Announces 2020 Annual Results

Hua Medicine (the"Company", Stock Code: 2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). During the Reporting Period, the Company continued to advance various clinical trials and R&D investments, successfully completed two Phase III registration trials for dorzagliatin in China, and achieved remarkable results in preparing for dorzagliatin's commercialization.

Dec 18

2020

Hua Medicine Successfully Completes Its Registration Phase III Trials. Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial

Hua Medicine (the"Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.